THE SCIENCE
Peptides Are Getting Better at Crossing the Line From Interesting Biology to Actual Drug Platforms
For years, peptides occupied an awkward position in drug development. They could bind targets with exquisite specificity, but they often came with baggage: poor...
THE SCIENCE
Survodutide Worked. Eighteen Percent Quit for GI Side Effects. Both Facts Matter.
Obesity-drug headlines have trained us to look for one number: weight loss.
Survodutide's latest Phase III data are a reminder that the second number can...
THE SCIENCE
The Triple-Agonist Era Is Here. Retatrutide Shows Why Three Hormones Change the Math.
The history of modern obesity pharmacology can be told as a story of receptor arithmetic.
Semaglutide made one pathway famous: GLP-1. Tirzepatide paired GLP-1 with...
THE SCIENCE
Survodutide Worked. Eighteen Percent Quit for GI Side Effects. Both Facts Matter.
Obesity-drug headlines have trained us to look for one number: weight loss.
Survodutide’s latest Phase III data are a reminder that the second number can...
THE SCIENCE
Novo’s $1.3 Billion Nanexa Deal Is Really a Bet on How Often You’ll Have to Inject
Obesity drug development loves new molecules because new molecules make clean headlines. A new receptor target sounds revolutionary. A new delivery technology sounds like...
THE SCIENCE
Ozempic vs. Mounjaro: A 636,525-Patient Study Just Shifted the Cardiovascular Argument
The GLP-1 conversation is obsessed with pounds. That made sense when the category was still proving it could produce weight loss once associated only...
THE SCIENCE
What Clinical Trials Can and Cannot Tell You
In the dynamic world of business and entrepreneurship, success is not just about having a great idea or a solid business plan. It requires...
